Trovagene announces successful completion of phase 1b trial of onvansertib in AML
Trovagene announced successful completion of its Phase 1b trial of onvansertib in combination with standard-of-care chemotherapy in acute myeloid leukemia and initiation of patient enrollment in Phase 2. The Phase 1b dose-escalation trial confirmed that onvansertib is safe and well tolerated. September 19, 2019